Lack of Correlation Between the CCR5-D32 Mutation and Acute Myeloid Leukemia in Iranian Patients

Publish Year: 1398
نوع سند: مقاله کنفرانسی
زبان: English
View: 401

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

SRCCG05_103

تاریخ نمایه سازی: 11 اسفند 1398

Abstract:

Introduction: Chemokines and their receptors are crucially important in the pathogenesis of acute myeloblastic leukemia AML . The CC chemokine receptor 5 CCR5 is a specific chemokine receptor for CC chemokine ligand 3 CCL3 , CCL4 and CCL5 which all play key roles in identifying cancer properties and localization of leukemia cells. It has been demonstrated that the known mutation in CCR5 gene CCR5-D32 leads to mal-expression of the .receptor and affect its function Purpose: The aim of this study was to determine the rate of CCR5-D32 mutation within Iranian AML patients Materials and Methods: In this study, blood samples were obtained from 60 AML patients and 300 healthy controls. The CCR5-D32 mutation was evaluated using Gap-PCR techniqueResults: Our results showed that CCR5-D32 mutation was not found in the patients, whilethree out of the controls had hetrozygotic form of this mutation. The rest of studied sam- .ples had the wild form of the gene Conclusion: According to these findings, it can probably be concluded that the CCR5-D32 is .not associated with susceptibility to AML in Iranian patients

Authors

Hossein Khorramdelazad

Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Yousef Mortazavi

Department of Molecular Medicine, Faculty of Medicine, Zanjan University of Medical Sciences Zanjan, Iran.

Mohammad Momeni

Department of Immunology, Faculty of Medicine, Rafsanjan University of Medical Sciences Rafsanjan, Iran.

Mohammad Kazemi Arababadi

Department of Immunology, Faculty of Medicine, Rafsanjan University of Medical Sciences,Rafsanjan, Iran ; Immunology of Infectious Diseases Research Center, Rafsanjan University of MedicalSciences, Rafsanjan, Iran

Behjat Kalantary Khandany

Department of Hematology-Oncology and BMT, Kerman University of Medical Sciences, Kerman, Iran.

Mozhgan Moogooei

Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.